MYMD MyMD Pharmaceuticals


Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On December 29, 2021, MyMD Pharmaceuticals, Inc. (the “Company”) held its 2021 annual meeting of stockholders (the “Annual Meeting”). At the Company’s Annual Meeting, holders of the Company’s voting securities with a total aggregate voting power of 31,371,678 votes were present in person or represented by proxy. The matters submitted for a vote and the related results are set forth below.

(1)Election of six directors to serve on our board of directors to serve for a term of one year or until their successors are elected and qualified:

Nominee Votes For Votes Withheld Broker Non-Votes
Chris Chapman 26,548,186 58,587 4,764,905
Craig Eagle 26,599,709 7,064 4,764,905
Christopher C. Schreiber 26,557,751 49,022 4,764,905
Joshua Silverman 24,859,416 1,747,357 4,764,905
Jude Uzonwanne 26,597,722 9,051 4,764,905
Bill J. White 26,138,800 467,973 4,764,905

The terms of the Company’s directors were scheduled to expire at the Annual Meeting, and the Board nominated all six directors for re-election at the Annual Meeting. At the Annual Meeting, Dr. Chris Chapman, Dr. Craig Eagle, Mr. Christopher C. Schreiber, Mr. Joshua Silverman, Mr. Jude Uzonwanne, and Mr. Bill J. White were elected as directors of the Board to serve for a term expiring at the Company’s 2022 annual meeting of stockholders.

(2)Ratification of the appointment of Morison Cogen LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021:

Votes For Votes Against Votes Abstaining
31,345,919 22,163 3,596

For more information about the foregoing proposals, see the Company’s definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on November 22, 2021, as supplemented, the relevant portions of which are incorporated herein by reference.

The results reported above are final voting results. No other matters were considered or voted upon at the Annual Meeting.